Abstract:AIM:To explore the effect of retinal photocoagulation combined with Ranibizumab or Conbercept on central macular thickness, visual acuity recovery and adverse reactions in patients with macular edema(ME)secondary to retinal vein occlusion(RVO).
METHODS: Totally 384 cases of patients(384 eyes)with RVO-ME in our hospital were divided into Group A(205 cases)and Group B(179 cases). Group A was given retinal photocoagulation and ranibizumab intravitreal injection, and Group B was given retinal photocoagulation and conbercept intravitreal injection. The postoperative central macular thickness(CMT), best corrected visual acuity(BCVA), intraocular pressure(IOP)and adverse reactions were compared between the two groups.
RESULTS:There was no significant difference in the total effective rate of fundus fluorescein angiography(FFA)between the two groups after 3mo(P>0.05). There were significant differences in BCVA in the two groups at each time point(P<0.05). There was no significant difference in BCVA between the two groups(P>0.05). The BCVA in two groups showed an upward trend after operation(P<0.05). There was a statistically significant difference in MCT in the two groups at each time point(P<0.05). There was no significant difference in MCT between the two groups(P>0.05). The MCT showed a downward trend in two groups after operation(P<0.05). There was no significant difference in IOP in the two groups at each time point(P>0.05). There was no significant difference in IOP between the two groups(P>0.05). And there was no significant increase in IOP after operation(P>0.05). The drug injection frequency within 3mo in Group B was significantly less than that in Group A(P<0.05), and there was no significant difference in the total incidence rate of adverse reactions between the two groups(5.4% vs 4.5%, P>0.05).
CONCLUSION: Retinal photocoagulation combined with ranibizumab or conbercept intravitreal injection can control the condition of RVO-ME patients, promote ME absorption, reduce CMT and improve visual acuity. The two drugs have effective time in single administration, and the drug administration frequency of conbercept are better than those of ranibizumab.
